|
|
New hydroxamic acid derivative Invention refers to a compound of formula [1] or its pharmaceutically acceptable salt, wherein R1 are R2 identical or different, and each of them represents a hydrogen atom, C1-6alkyl group, C3-8cycloalkyl group or C1-6alkoxy group (C1-6alkyl group, C1-6alkoxy group and C3-8cycloalkyl group can be substituted by 1-3 substitutes, which are identical or different from a halogen atom, C1-6alkoxy group); R3 represents a hydrogen atom or C1-6alkyl group; R4 represents a hydrogen atom, C1-6alkyl group, C3-8cycloalkyl group (which can be substituted by substitutes specified in the patent claim), a heterocyclic group specified in pyridine; A1 represents a bivalent aryl group, a bivalent heterocyclic group specified in pyridyl, pyrazinyl, thiophenyl, or C3-8cycloalkylene group (bivalent aryl group can be substituted by 1-4 substitutes, which are identical or different from the following group of substitutes Ra, which are specified in the patent claim); L represents -C≡C-, -C≡C-C≡C-, -C≡C-(CH2)m-O-, CH=CH-, -CH=CH-C≡C-, -C≡C-CH=CH-, -O-, -(CH2)m-O-, -O-(CH2)m-, C1-4alkylene group or a bond; m means 1, 2 or 3; A2 represents a bivalent aryl group, a bivalent heterocyclic group (presented in the patent claim), C3-8cycloalkylene group, C3-8cycloalkenylene group, C1-4alkylene group or C2-4alkenylene group (which can be substituted by 1-4 substitutes, which are identical or different and specified in a group of substitutes Rb, which is specified in the patent claim); W represents R6-X1-, R6-X2-Y1-X1-, R6-X4-Y1-X2-Y3-X3-, Q-X1-Y2-X3- or Q-X1-Y1-X2-Y3-X3-; Y2, Y1, Y3, n, X1, X3, X2, X4, Q, R6, R7, R8 and R9 are presented in the patent claim. The compounds of formula [1] possess antimicrobial activity on gram-negative bacteria by LpxC inhibition. |
|
Invention relates to biotechnology and particularly to synthetic peptides with immunostimulating properties, and can be used in medicine. A series of peptides is synthesised, the peptides differing on chemical structure from existing biologically active Alloferon and Allostatin peptides. The difference lies in that in position 6 of the His-Gly-Val-Ser-Gly-X-Gly-Gln-His-Gly-Val-His-Gly structure, instead of histidine or tryptophan typical for said peptides, there are other amino acids of the aliphatic and aromatic series, as well as chemical modifications thereof. The obtained peptides are used in an immunomodulating and antiviral pharmaceutical composition. |
|
Replication-deficient, dominant and negative recombinant virus of herpetic fever 2, the vaccine and the method of patient immunisation against the infection HSV-1 or HSV-2 are offered. The recombinant virus contains two sequences coding D HSV-2 glycoprotein, linked with ICP4 promoters in the genome, the latter are connected with the sequences of tetracycline operators, and two sequences coding UL9-C535C protein which are linked with hCMV promoters linked with the sequences of tetracycline operators. Note that the virus doesn't contain the sequence coding ICP0 protein. The vaccine containing the named recombinant virus is safe and efficient against the infections HSV-1 or HSV-2 due to expression of the dominant and negative form of UL9-C535C polypeptide and use of tetracycline-induced activation and deactivation of genes. The method of immunisation of patients against HSV-1 or HSV-2 using the offered vaccine is also offered. |
|
Pharmaceutical composition for treating mycotic infections Invention represents a pharmaceutical composition applicable for local nail application and containing from approximately 1 wt % to approximately 35 wt % of an urea component per total weight of the composition, from approximately 40 wt % to approximately 80 wt % of a diol component per total weight of the composition, from approximately 1 wt % to approximately 20 wt % of an organic acid component per total weight of the composition, from approximately 5 wt % to approximately 12 wt % of glycerol per total weight of the composition, and an amount of an aqueous base sufficient to provide final pH of the composition ranging from approximately 2 to approximately 6. |
|
Agent for treating and preventing viral skin new growths What is described is an antiviral emulsion agent based on interferon inducer for topical application. The base contains Vaseline or Vaseline oil, T-2 emulsifier, as well as a solution of amphiphilic complex or single-chain high-polymeric RNA of Saccharomyces cerevisiae containing short double-stranded regions with oleic acid enriched with sodium oleate (up to 10%). |
|
|
Invention refers to new indanone derivatives of formula I wherein the radicals A1-A4, D, E, X and G1-G4 have the values specified in the description, to their pharmaceutically acceptable salts or enantiomers, as well as to methods for producing them, and a pharmaceutical composition applicable for preventing and treating a viral disease and containing the above compounds as an active ingredient. |
|
Copper (ii) imidazolemalate, demonstrating antibacterial activity, and method of obtaining thereof Invention relates to coordination compounds of metals, namely to copper (II) imidazolemalate of general formula Cu(C3H4N2)C4H4O5 · 2H2O, which demonstrates antibacterial activity in wide range of concentrations. Method of thereof obtaining is also claimed. |
|
![Benzo[1,2,4]thiadiazine inhibitors of hepatitis b virus replication and pharmaceutical composition for treating hepatitis b](http://img.russianpatents.com/img_data/1232/12327341-s.jpg)
|
Inventions refer to the new inhibitors of hepatitis B virus replication, representing 1,1-dioxo-1,4-dihydro-2H-benzo[1,2,4]thiadiazin-3-ones of general formula 1, their pharmaceutically acceptable salts and/or hydrates. In general formula |
|
Medicinal agent for preventing and/or treating hepatocellular carcinoma Invention refers to pharmaceutical industry and represents a pharmaceutical agent applicable for post-treatment recurrent hepatocellular carcinoma inhibition and containing peretinoin combined with L-isoleucine, L-leucine and L-valine. |
|
Invention refers to chemical-pharmaceutical industry and represents an injection solution for treating viral diseases specified in H1N1, H3N2, H5N1 influenza, tick-borne encephalitis and West Nile fever, containing triazavirin in an amount of 0.05-4.0 wt %, additives in an amount of 0.1-30.0 wt % and water up to 100 wt %. |
![4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride hydrochloride hexahydarate for treating herpetic infection, pharmaceutical composition for local application](http://img.russianpatents.com/img_data/1232/12322989-s.jpg)
|
Invention refers to medicine and represents a pharmaceutical composition in the form of a cream or gel for treating a herpes viral infection, containing 4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride dihydrochloride hexahydrate. The invention consists in a method of treating or preventing a herpetic infection in a human or animal. |
|
What is presented is an agent for therapeutic treatment and prevention of fungal diseases of skin and appendages of skin, and extensive and systemic fungal infections of human and animal skin, characterised by the fact that it represents benzyl benzoate and a pharmaceutical composition containing at least 0.1 wt % of this agent High activity of benzyl benzoate on most species of fungal agents and high therapeutic efficacy have been shown. |
|
|
Non-toxic recombinant shiga toxin type 2 (stx2) Invention refers to molecular and medical biology, and particularly to genetically modified proteins. What is presented is Stx2[E167Q/R170H] protein, which carries point substitutions of two amino acid residues in a catalytic site region of Stx2A sub-unit, responsible for protonation of adenine of A4324 residue of 28S RNA of eucariotic ribosomes, namely a point substitution of [E167Q] glutamic acid residue in position 167 by a glutamine residue and a point substitution of [R170H] arginine residue in position 170 by a histidine residue. The produced protein has more than 106 times lower cytotoxicity and high immunogenicity. |
|
Anti-cxcr4 antibodies for treatment of hiv infection Claimed invention relates to field of immunology. Claimed is antibody against human CXCR4 or its functional fragment, which are characterised by the fact that they contain light and heavy chains, which each contain 3 respective CDR. Described are versions of nucleic acids for antibody expression; vector for antibody expression, based on said NA, host cell for obtaining antibody, which contains said vector, and method for obtaining antibody, using cell cultivation. Disclosed is pharmaceutical composition, capable of binding human CXCR4 based on antibody. Described is method of screening and/or identification of molecules as anti-viral medications, CXCR4-antagonists. |
|
Topical fungicidal agents for treating nail disorders Invention refers to pharmaceutics. Described are anhydrous agents for topical applications, containing one or more C1-C4 alkyl esters of lactic acid, malic acid, tartaric acid or citric acid, and physiologically acceptable inert filling agents for treating nail disorders caused by mycosis and for nail care. The agents according to the invention are also applicable in veterinary science for treating a fungal infection of hooves, pincers and claws of domestic animals and warm-blooded animals, and captured wild animals. |
|
|
Derivatives of (4-methylsulphonylaminophenyl)-quinoline, useful in treatment of hepatitis c Invention relates to field of organic chemistry, namely to compound, selected from the group of N-{4-[7-tert-butyl-8-methoxy-5-(2-oxo-1,2-dihydro-pyridin-3-yl)-quinolin-2-yl]phenyl}-methanesulphonamide; N-{4-[7-tert-butyl-8-methoxy-5-(6-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-quinolin-2-yl]-phenyl}- methanesulphonamide; and N-{4-[7-tert-butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-8-methoxy-quinolin-2-yl]-phenyl}- methanesulphonamide; or to its pharmaceutically acceptable salt. The invention also relates to application of said compound for treatment or prevention of infection with hepatitis C virus (HCV) and for manufacturing thereof based medication. |
|
Group of inventions refers to medicine and concerns a composition for subcutaneous administration, containing PEGylated interferon alpha and additives, particularly edetate disodium dehydrate, sodium acetate trihydrate, glacial acetic acid, an osmotic agent. The group of inventions also concerns a method for producing the above composition; a kit comprising a syringe or flask filled with the above composition, and an instruction for use. |
|
Kibdelos porangium extracts as antibacterial agents Invention refers to an antibacterial composition containing one or more refined compounds specified in compounds of formula: |
|
Invention relates to application of formula (I) compound, for preparation of medication, used for treatment of chronic obstructive pulmonary disease. In compound (I) A represents aryl group, selected from phenyl; B represents aryl group, selected from phenyl or pyridyl; X represents carbon atom or nitrogen atom; R represents substituted or non-substituted groups, selected from heteroaryl groups, including pyridyl, thienyl, furyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidinyl and pyrazinyl, and heterocyclic groups, including morpholine, thiomorpholine, piperazine, piperidine, piperidin-4-one, pyrrolidine, pyrrole-2,5-dione, thiazolidine, 1-oxido-thiazolidine and 1,1-dioxido-1,3-thiazolidine; where heterocyclic group is optionally substituted with substituents, independently selected from substituted or non-substituted (C6)aryl, -CH2-C6aryl, -CH2-heteroaryl, CO-C6aryl, -CO-heteroaryl, -CS-heteroaryl, -CO-C3-6cycloalkyl, cyano(C1-4)alkyl, -O-methyloxime, -SO2Cl, formyl, or other substituted or non-substituted heterocyclic group, selected from pyridyl, pyrimidinyl and piperidinyl; where binding of heterocyclic group to pyrimidine ring takes place through carbon or nitrogen atom; and where group R or substituent of heterocyclic group R are optionally substituted. Other substituents are given in invention formula. |
|
Antiviral heterocyclic compounds Invention refers to new compounds of formula (I), which possess the properties of HCV NS5B RNA-polymerase inhibitor. The compounds may be used for treating or preventing an infection caused by hepatitis C virus (HCV). In formula (I), X represents CH or N, R1 is specified in a group consisting of R1a, R1c : wherein R1a is optionally substituted by C1-6alkyl, C1-6alkoxy or hydroxy, and wherein R1c is optionally substituted by C1-6alkyl; R2 represents (a) aryl specified in phenyl, or (b) NRaRb, wherein the above aryl is optionally substituted by (CH2)nNRcRd; Ra and Rb together with a nitrogen atom, to which they are attached, represent 5-merous heterocyclic amine substituted by (CH2)nNRcRd group, wherein n means a number from zero to two; Rc and Rd independently represent hydrogen, O2SR4, wherein R4 represents C16alkyl; R3 represents CR4aR4bR4c, wherein: 1) R4a, R4b and R4c are independently specified in C1-3alkyl. |
|
Invention relates to field of biochemistry, in particular to biologically active compounds, which demonstrate antibacterial activity. Claimed is natural glycopeptide antibiotic INA 5812, which can be applied as medication in medical practice. The invention also relates to strain-producer Streptomyces roseoflavus INA-As-5812, which forms antibiotic INA 5812, and method for obtaining antibiotic INA 5812. |
|
|
Pharmaceutical composition for influenza prevention Invention consists in a pharmaceutical intranasal composition for influenza prevention, which contains oxidised dextran having a molecular weight of 40-70 kDa in the concentration of 5-10 wt % as an active component, and a pharmaceutically acceptable solvent. |
|
Method for producing antibacterial preparation of manna gum leaves Method for producing an antibacterial preparation by extracting manna gum leaves in petroleum ether with a boiling point of 40-70°C; the extracts are combined, boiled down, dried; the dry residue is dissolved in 95% ethanol in the certain environment. |
|
Derivatives of 1-(1-adamantyl)ethylamine-n-acylaminoacides and their anti-influenza activity Invention relates to novel amino acid derivatives of 1-(1-adamantyl)ethylamine of general formula given below, and namely to compounds 1-3 in which , (compound 1); R1 = H, (compound 2) and , (compound 3). Claimed compounds have selective antiviral activity with respect to influenza A viruses, acts on strains, resistant to action of rimantadine hydrochloride, and can be applied in pharmacology and virology. |
|
Immunometabolic formulation with antimicrobial activity Invention refers to veterinary science and is applicable for a preventive and intensive therapy of purulent septic and gastrointestinal focal diseases, stimulation of immunity system and metabolic processes in animals. Object of the invention is a method for producing a new formulation based on iodine, succinic acid and ASD second fraction, possessing immunometabolic and antimicrobial activity. |
|
|
Using ep4 receptor antagonists in treating il-23-mediated diseases Invention refers to a compound with EP4 receptor antagonist activity or its pharmaceutically acceptable salt, which is effective in treating an immune disease or allergy. This invention also refers to a compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt with EP4 receptor antagonist activity, which is effective in treating an immune disease or allergy. This invention also refers to a pharmaceutical composition for treating an immune disease or allergy, which contains a therapeutically effective amount of the compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt. |
|
Individual is examined to measure serum albumin, total cholesterol and high-density lipoprotein (HDL). The serum albumin level making at least 1.5 g/dl, and the total cholesterol level making at least 40 mg/dl, and/or the high-density lipoprotein level making at least 20 mg/dl require administering an emulsion. The emulsion contains (i) a phospholipid, (ii) a neutral lipid and (iii) a cholate salt. |
|
Antiretroviral compounds and use thereof Invention refers to new compounds of formula (I) and their pharmaceutically acceptable salts, which inter alia inhibit hepatotropic hepatitis C virus and are applicable in treating hepatitis C virus. In formula (I) R1 is specified in a group consisting of |
|
Novel synergistic pharmaceutical composition for topical application Group deals with pharmaceutical composition for prevention and treatment of wounds or burn wounds, which contains mitogenic protein, bactericidal preparation silver sulphadiasine and bacteriostatic preparation chlorhexidine gluconate. Group of inventions also deals with pharmaceutical composition for prevention and treatment of wounds or burn wounds, containing rh-EGF, silver sulfadiazine, pemulen TR-1, carbopol Ultrez, sodium methylparaben, sodium propylparaben, mannite, triethanolamine and water. |
|
Invention relates to field of medicine, namely to virology, and deals with treatment and prevention of infectious diseases, caused by influenza virus with surface antigen of H1N1 type in domestic animals and poultry. For this purpose effective quantity of medication, representing homoeopathically activated potentiated form, obtained by uniform reduction of concentration by successive dilution of matrix solution of affinity purified antibodies to human gamma-interferon in neutral solvent with multiple shaking of each obtained dilution. |
|
|
Pharmaceutical set for prevention and/or treatment of bacterium-caused disease, which includes honeysuckle extract, containing iridoid compounds, and antibiotic. Application of pharmaceutical composition or pharmaceutical set for obtaining medications for prevention and/or treatment of bacterium-caused disease. Application of honeysuckle extract, containing iridoid compounds, for obtaining medications for reversion of bacteria resistance, where honeysuckle extract contains secologanic acid in specified quantity. |
![Substituted 2-[(1z)-1-(3,5-diaryl-1,3,4-thiadiazol-2(3h)-yliden)methyl]-3,5-diaryl-1,3,4-thiadiazol-3-ium chlorides and method of obtaining thereof](http://img.russianpatents.com/img_data/1228/12286780-s.jpg)
|
Invention relates to novel individual compounds of class of mesoionic heterocyclic systems - substituted chlorides of 2-[(1Z)-1-(3,5-diaryl-1,3,4-thiadiazol-2(3H)-ylidene)methyl]-3,5-diaryl-1,3,4-thiadiazol-3-ium of general formula I, where: R = 3,5-diFC6H4; R1 = 4-FC6H4 (Ia); R = 4-FC6H4; R1 = Ph (Ib); R = 3,5-diFC6H4; R1 = Ph (Ic); R = 3,5-diClC6H4; R1 = Ph (Id); R = 4-NO2C6H4; R1 = Ph (Ie); R = Bn; R1 = Ph (If). Substituted chlorides, presented by formula , are obtained by interaction of substituted N'-arylthiobenzhydrazide with malonyldinitrile in ratio 2:1 in medium of polar organic solvent (demethylformamide) and hydrogen chloride, and reaction mixture is initially saturated by dry hydrogen chloride, and then, without stopping hydrogen chloride supply, heated to 60°C and exposed for an hour with the following product separation. To separate product cooled reaction mixture is poured out on finely-milled ice, mixed and precipitated sediment is filtered out. |
|
Polysaccharide of tamarind seed for application in treatment of microbial infections Claimed invention relates to pharmaceutical industry, namely to medication for prevention and/or treatment of microbial infections. Medication for prevention and/or treatment of microbial infections, containing polysaccharide of tamarind seed and extract of Helichrysum italicum, Echinacea spp., Aesculus hippocastanum, Zanthoxylum bungeanum or their mixture in weight ratio 1:1 of tamarind seed polysaccharide and extract. Antimicrobial composition for skin and mucosa. Application of polysaccharide of tamarind seed in combination with extract of Helichrysum italicum, Echinacea spp., Aesculus hippocastanum, Zanthoxylum bungeanum or their mixture for obtaining medication for prevention and/or treatment of microbial infections. |
|
![1-[ω-aryloxyalkyl(benzyl)]-substituted 2-aminobenzimidazoles, having activity on influenza virus](http://img.russianpatents.com/img_data/1228/12285091-s.jpg)
|
1-[ω-aryloxyalkyl(benzyl)]-substituted 2-aminobenzimidazoles, having activity on influenza virus Invention relates to organic chemistry and particularly to novel benzimidazole derivatives of formula 1a-f: |
|
Group of inventions relates to medicine, namely to otorhinolaryngology, and are intended for treatment of aural infections, caused by quinolone-resistant microbes, in particular Ciprofloxacin-resistant microbes. Pharmaceutical composition includes finafloxacin or its pharmaceutically acceptable salt in concentration 0.1-1.0 wt/vol %. Also the method of treating acute external otitis or acute otitis media with tympanostomy tubes, caused by quinolone-resistant microbes, in particular Ciprofloxacin-resistant microbes is provided. Claimed method includes instillation of aural composition for local application, which includes finafloxacin in concentration 0.1-1.0 wt/vol % into subject's external ear canal. |
|
Invention relates to microbiology and can be applied in pharmacology and medicine. The strain has antibacterial and antifungal activity against pathogenic and opportunistic microflora. After a 18-hour incubation of the claimed strain with indicator strains in anaerobic conditions at 37°C the zone of delay of the Streptococcus agalactia, Bacteroides fragilis, Gardnerella vaginalis growth constitutes 3.83 mm, 9.50 mm, 15.00 mm respectively and in anaerobic conditions for Staphylococcus aureus the zone of growth delay constitutes 22.67 mm, for Candida albicans - 6.00 mm. |
|
|
Method of treating patients with pleural effusion of various aetiology Invention refers to medicine, namely pulmonology, phthisiology and thoracic surgery, and may be used for treating patients with pleural effusion of various aetiology. That is ensured by a standard drug therapy, effusion aspiration from a pleural cavity and complex use of medicinal preparations and laser exposure. That involves conducting a combination laser therapy by means of Matrix-VLOK apparatus with intrapleural and intravenous laser exposure alternated every second day. The exposure is conducted at wavelength 0.365 mcm at disposable end-face output power 1-1.5 mW and pulse frequency 80 Hz in the continuous radiation mode for 10 minutes. After the effusion is aspirated from the pleural cavity, cefazolin 1.0 g is introduced therein. The therapeutic course makes from 3 to 7 procedures. |
|
Invention relates to novel compounds used as an antibacterial agent in the pharmaceutical industry, having the formula , where R= |
![1,6-diazabicyclo[3,2,1]octan-7-onА derivatives and using them in treating bacterial infections](http://img.russianpatents.com/img_data/1227/12279434-s.jpg)
|
1,6-diazabicyclo[3,2,1]octan-7-onА derivatives and using them in treating bacterial infections Invention refers to a new heterocyclic compound of general formula (I) or its stereoisomer, or its pharmaceutically acceptable salt, wherein Q means oxadiazol, thiadiazole or tetrazole; R1 means: (b) (CO)n-R3 or (c) COOR4, n=0 or 1; R2 means SO3M, M means hydrogen or cation; R3 means: (a) C1-C6-alkyl optionally substituted by one or more substitute independently specified in halogen, NR6R7, heterocyclyl or aryl, (b) NR6R7, (c) CONR6R7, (d) aryl, (e) heterocyclyl, or (f) heteroaryl optionally substituted by CONR6R7, R4 means (a) hydrogen, or (b) C1-C6-alkyl; each R6 and R7 independently means (a) hydrogen or (b) R6 and R7 are coupled together to form a four- to seven-merous ring, wherein cycloalkyl represents 3-7-merous cyclic hydrocarbon radical; heterocyclyl represents 4-7-merous cycloalkyl group containing one or more heteroatoms specified in nitrogen, oxygen or sulphur; aryl represents monocyclic or polycyclic hydrocarbon containing 6-14 atoms in the ring; heteroaryl represents monocyclic or polycyclic heteroaryl, wherein one or more carbon atoms are substituted by heteroatoms specified in nitrogen, oxygen or sulphur. The invention also refers to a pharmaceutical composition based on the compound of formula (I) and a method for preventing or treating a bacterial infection based on using the compound of formula (I). |
|
Group of inventions relates to medicine and deal with mucosal vaccine, producing antigen-specific IgA of mucosa and IgG of blood at levels, capable of inducing effective immune induction and effect of infection prevention, which includes: (a) AD-carrier, consisting of synthetic peptide and mixture of dipalmitoylphosphatidylcholine, phosphatidylglycerol and palmitic acid; (b) carboxyvinyl polymer; and (c) antigenic protein. Group of inventions also deals with method of obtaining said mucosal vaccine. |
|
Antibacterial pharmaceutical composition for treatment of farm animals and poultry Composition comprises a compound from the group of fluoroquinolones, apramycin sulphate and auxiliary substances. |
|
Antimicrobial agents and methods of application thereof Invention relates to medicine. Claimed is an antimicrobial agent, containing: (a) water; (b) from approximately 20 vol% to approximately 60 vol% of a low-molecular alcohol; (c) from approximately 0.05 vol% to approximately 40 vol% of peroxide or a peroxide-forming agent; and (d) EDTA in a concentration from approximately 5 mg/ml to approximately 50 mg/ml. |
|
|
N-(2-acetamidopurin-6-yl)glycine, which has anti-tuberculosis activity Invention relates to novel N-(2-acetamidopurin-6-yl)glycine of lower given formula , which has anti-tuberculosis activity, including with respect to strains of mycobacteria with multi-drug-resistance. Invention can be applied in medicine and veterinary. |
|
Nitrogen-containing compounds and application thereof Invention relates to formula (I) compound or its stereoisomer, or its pharmaceutically acceptable salt, where M stands for cation, and its application in prevention and treatment of bacterial infections. |
|
Group of inventions refers to medicine and may be used in treating infectious diseases. A pharmaceutical composition contains one beta-lactam antibiotic or its pharmaceutically acceptable salt, sulbactam or its pharmaceutically acceptable salt and trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide or its pharmaceutically acceptable salt. The methods according to the invention concern treating a bacterial infection by administering the above composition. |
|
Treating and preventing hiv infection Group of inventions refers to the long-term use of an parenteral formulation for producing a medicinal preparation for treating a HIV-infected individual with the above preparation applicable for subcutaneous or intramuscular injections and consists of brecanavir, or its salt in the form of an aqueous micro- or nanoparticle suspension containing Polysorbate 20, and is administered at regular intervals from 6 to 12 months, and to the above pharmaceutical composition. |
|
Pencil contains emulsion or white wax, vegetable oil and the substance preventing growth and development of microorganisms. The named substance of the pencil is amber, propolis, pine thus or their mix. Amber is used in the form of solution of particles with the size 0.6-5 mcm in vegetable oil at the mass ratio 1:3. Ratio of components is as follows, in wt %: the named amber 30-50, propolis up to 6, pine thus up to 20, while or emulsion wax - the rest. At preparation of composition the solution is homogenised in ultrasonic field with the power density 1-10 W/cm3 and with the frequency 22 kHz within 10 min. |
|
Invention may be applicable to prevent neutropenia developing in the patients suffering chronic hepatitis C (CHC) in response to conducting an antiviral combination therapy (ACT). The method for preventing neutropenia in the CHC patients receiving the ACT is characterised by introducing autoblood haemolysate (ABH) 20.0 ml intravenously daily to the CHC patients in need of the ACT and having a high risk of ACT-associated neutropenia, 10 days exactly before the ACT beginning; from the very beginning and throughout the entire course of the ACT, the ABH intravenous administration continues in the same dose, however performed every 7 days. During the ABH intravenous administration, patient's blood 10.0 ml is taken from median cubital vein into a syringe 20.0 ml 50% pre-filled with distilled water; thereafter, leaving a puncture needle in the vein, the ABH produced in the syringe is introduced back into the vascular bed. |
|
Method of treating infected wounds and ulcers in cattle Invention refers to veterinary science and aims at treating infected wounds and ulcers in cattle. A method involves covering an involved side with Lyubisan-ECO mixed with a binding agent taken in ratio 1:1. The above binding agent is the antiseptic agent Ichthyol Ointment. The involved site is preliminary treated with the combined antibacterial preparation Tricyllin in an amount of no more than 2 g/cm2. That is followed by applying a mix of Ichthyol Ointment and Lyubisan-ECO. The wound is bandaged, and the bandage and a small surrounding area are additionally dusted with Lyubisan-ECO power to form a protecting crust having antimicrobial properties. The procedure is repeated 1-3 days later. |
|
|
Therapeutic agent for treating viral hepatitis c What is presented is a therapeutic agent containing modified pseudovirions of MS2 bacterial virus a coating of which is generated by proteins A and B of MS2 bacterial virus, whereas a portion of genome RNA coding replicase is replace by RNA able to kill cells selectively, which are infected with hepatitis C virus or its RNA replicon; a genome of modified pseudovirions of MS2 bacterial virus is characterised by the nucleotide sequence SEQ ID NO 1. |
Another patent 2551303.